Vitrolife AB (publ) (VITR.ST)
SEK 154.6
(-0.19%)
SEK 154.6
(-0.19%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -3.18 Billion SEK | 16.38% |
| 2022 | 993 Million SEK | 72.43% |
| 2021 | 579.6 Million SEK | 30.01% |
| 2020 | 438.64 Million SEK | -25.4% |
| 2019 | 594.39 Million SEK | 23.29% |
| 2018 | 450.66 Million SEK | 18.4% |
| 2017 | 407.85 Million SEK | 33.99% |
| 2016 | 303.77 Million SEK | 15.71% |
| 2015 | 281.12 Million SEK | 56.1% |
| 2014 | 171.13 Million SEK | 36.08% |
| 2013 | 102.7 Million SEK | 59.9% |
| 2012 | 71.64 Million SEK | 86.91% |
| 2011 | 64.18 Million SEK | -18.54% |
| 2010 | 57.49 Million SEK | 67.17% |
| 2009 | 36.42 Million SEK | 12.1% |
| 2008 | 27.12 Million SEK | 31.18% |
| 2007 | 20.67 Million SEK | 24.61% |
| 2006 | 16.59 Million SEK | -25.13% |
| 2005 | 25.05 Million SEK | 69.95% |
| 2004 | 14.61 Million SEK | -70.54% |
| 2003 | 41.87 Million SEK | -64.5% |
| 2002 | 124.69 Million SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 347 Million SEK | 19.85% |
| 2024 Q1 | 265 Million SEK | 106.79% |
| 2024 Q3 | 173 Million SEK | -46.93% |
| 2023 FY | - SEK | 16.38% |
| 2023 Q1 | 159 Million SEK | 67.37% |
| 2023 Q2 | 187 Million SEK | 17.61% |
| 2023 Q3 | 180 Million SEK | -3.74% |
| 2023 Q4 | 304 Million SEK | 68.89% |
| 2022 Q2 | 174 Million SEK | 29.85% |
| 2022 Q1 | 134 Million SEK | 79.8% |
| 2022 Q3 | 178 Million SEK | 2.3% |
| 2022 Q4 | 95 Million SEK | -46.63% |
| 2022 FY | - SEK | 72.43% |
| 2021 Q1 | 142.47 Million SEK | -2.14% |
| 2021 Q2 | 111.14 Million SEK | -21.99% |
| 2021 Q4 | 74.52 Million SEK | -47.58% |
| 2021 FY | - SEK | 30.01% |
| 2021 Q3 | 142.18 Million SEK | 27.93% |
| 2020 Q4 | 145.59 Million SEK | 29.45% |
| 2020 FY | - SEK | -25.4% |
| 2020 Q2 | 16.41 Million SEK | -82.51% |
| 2020 Q3 | 112.47 Million SEK | 585.38% |
| 2020 Q1 | 93.8 Million SEK | -32.05% |
| 2019 Q3 | 130.47 Million SEK | 6.13% |
| 2019 Q4 | 138.05 Million SEK | 5.8% |
| 2019 Q2 | 122.93 Million SEK | 18.74% |
| 2019 FY | - SEK | 23.29% |
| 2019 Q1 | 103.53 Million SEK | -3.13% |
| 2018 Q4 | 106.87 Million SEK | 2.73% |
| 2018 Q2 | 98.48 Million SEK | 9.83% |
| 2018 Q3 | 104.03 Million SEK | 5.64% |
| 2018 Q1 | 89.66 Million SEK | 2.66% |
| 2018 FY | - SEK | 18.4% |
| 2017 Q4 | 87.34 Million SEK | 7.69% |
| 2017 FY | - SEK | 33.99% |
| 2017 Q2 | 94.6 Million SEK | 20.81% |
| 2017 Q1 | 78.31 Million SEK | -1.15% |
| 2017 Q3 | 81.1 Million SEK | -14.27% |
| 2016 Q3 | 56.69 Million SEK | -8.23% |
| 2016 FY | - SEK | 15.71% |
| 2016 Q1 | 52.01 Million SEK | -27.63% |
| 2016 Q2 | 61.78 Million SEK | 18.76% |
| 2016 Q4 | 79.22 Million SEK | 39.74% |
| 2015 FY | - SEK | 56.1% |
| 2015 Q4 | 71.87 Million SEK | 8.59% |
| 2015 Q1 | 39.45 Million SEK | -2.93% |
| 2015 Q2 | 50.5 Million SEK | 28.01% |
| 2015 Q3 | 66.19 Million SEK | 31.06% |
| 2014 Q2 | 33.6 Million SEK | 12.31% |
| 2014 Q1 | 29.92 Million SEK | 30.42% |
| 2014 FY | - SEK | 36.08% |
| 2014 Q4 | 40.64 Million SEK | -7.03% |
| 2014 Q3 | 43.71 Million SEK | 30.1% |
| 2013 FY | - SEK | 59.9% |
| 2013 Q2 | 18.63 Million SEK | 9.91% |
| 2013 Q1 | 16.95 Million SEK | -23.99% |
| 2013 Q3 | 23.08 Million SEK | 23.88% |
| 2013 Q4 | 22.94 Million SEK | -0.62% |
| 2012 FY | - SEK | 86.91% |
| 2012 Q3 | 14.64 Million SEK | 8.12% |
| 2012 Q4 | 22.3 Million SEK | 52.36% |
| 2012 Q1 | 15.1 Million SEK | 271.05% |
| 2012 Q2 | 13.54 Million SEK | -10.37% |
| 2011 Q1 | 10.13 Million SEK | -61.44% |
| 2011 FY | - SEK | -18.54% |
| 2011 Q4 | 4.07 Million SEK | -71.65% |
| 2011 Q3 | 14.36 Million SEK | 14.06% |
| 2011 Q2 | 12.59 Million SEK | 24.25% |
| 2010 Q1 | 10 Million SEK | 50.94% |
| 2010 Q2 | 8.67 Million SEK | -13.25% |
| 2010 Q3 | 5.87 Million SEK | -32.35% |
| 2010 Q4 | 26.28 Million SEK | 347.66% |
| 2010 FY | - SEK | 67.17% |
| 2009 FY | - SEK | 12.1% |
| 2009 Q2 | 7.79 Million SEK | 0.0% |
| 2009 Q4 | 6.62 Million SEK | -7.89% |
| 2009 Q3 | 7.19 Million SEK | -7.67% |
| 2008 FY | - SEK | 31.18% |
| 2007 FY | - SEK | 24.61% |
| 2006 FY | - SEK | -25.13% |
| 2005 FY | - SEK | 69.95% |
| 2004 FY | - SEK | -70.54% |
| 2003 FY | - SEK | -64.5% |
| 2002 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Acarix AB (publ) | -77.12 Million SEK | -4029.82% |
| ADDvise Group AB (publ) | 411.9 Million SEK | 873.246% |
| ADDvise Group AB (publ) | 411.9 Million SEK | 873.246% |
| Arcoma AB | 6.24 Million SEK | 51076.312% |
| Bactiguard Holding AB (publ) | -89.98 Million SEK | -3439.597% |
| BICO Group AB (publ) | 322.3 Million SEK | 1088.21% |
| Boule Diagnostics AB (publ) | 65.97 Million SEK | 4927.294% |
| CellaVision AB (publ) | 207.24 Million SEK | 1636.828% |
| Clinical Laserthermia Systems AB (publ) | -68.4 Million SEK | -4556.025% |
| Chordate Medical Holding AB (publ) | -27.94 Million SEK | -11298.205% |
| C-Rad AB (publ) | 48.9 Million SEK | 6612.76% |
| Duearity AB (publ) | -24.77 Million SEK | -12753.626% |
| Dignitana AB (publ) | -264 Thousand SEK | -1206339.394% |
| Episurf Medical AB (publ) | -87.7 Million SEK | -3531.699% |
| Getinge AB (publ) | 5.92 Billion SEK | 153.719% |
| Scandinavian Real Heart AB (Publ) | -67.25 Million SEK | -4636.055% |
| Iconovo AB (publ) | -35.33 Million SEK | -8913.607% |
| Integrum AB (publ) | 8.76 Million SEK | 36452.102% |
| Luxbright AB (publ) | -23.86 Million SEK | -13244.933% |
| Mentice AB (publ) | 28.87 Million SEK | 11131.067% |
| OssDsign AB (publ) | -122.02 Million SEK | -2510.206% |
| Paxman AB (publ) | 31.22 Million SEK | 10298.854% |
| Promimic AB (publ) | -3.68 Million SEK | -86354.964% |
| Qlife Holding AB (publ) | -150.5 Million SEK | -2016.209% |
| SciBase Holding AB (publ) | -51.82 Million SEK | -6045.208% |
| ScandiDos AB (publ) | -13.35 Million SEK | -23746.96% |
| Sectra AB (publ) | 615.06 Million SEK | 617.836% |
| Sedana Medical AB (publ) | -51.67 Million SEK | -6063.641% |
| Senzime AB (publ) | -118.82 Million SEK | -2580.457% |
| SpectraCure AB (publ) | -20.96 Million SEK | -15089.089% |
| Stille AB | 56.04 Million SEK | 5783.339% |
| Xvivo Perfusion AB (publ) | 126.57 Million SEK | 2616.315% |